Lipo-C · Lipotropic Injectionnot a peptide, not even one molecule — a compounded "fat-loss shot" whose evidence belongs to its oral parts

Real ingredients, a real liver rationale, a thin blend case.

Lipo-C is the atlas's first entry that's both not-a-peptide and not-a-molecule — a compounded lipotropic injection, essentially the classic MIC blend (methionine + inositol + choline) plus L-carnitine and usually a B-vitamin. Its honest picture has three parts, mirroring the GLOW/KLOW pattern but in the metabolic-cofactor world. First, each ingredient has legitimate biochemistry in hepatic fat handling and energy metabolism. Second, the genuine human evidence is for the individual components taken orally — L-carnitine and inositol meta-analyses, choline in deficiency — not for this injected blend, which has no controlled trial. Third, it's marketed as a "fat-loss shot" but is properly an adjunct to diet and exercise, is not FDA-approved for weight loss, and is compounded (so composition varies by pharmacy). The page keeps the component evidence and the blend claim honestly separate.

Four nutrients, four liver/energy jobs, one unproven sum.

Lipo-C has no single mechanism — it's a deliberate stacking of cofactors that each touch a different bottleneck in how the liver processes and exports fat. Methionine and choline are methyl donors feeding phosphatidylcholine synthesis (needed to package and export triglycerides as VLDL); inositol participates in insulin signaling and hepatic lipid export; L-carnitine shuttles fatty acids into mitochondria for β-oxidation; and dexpanthenol/B-vitamins support the coenzyme-A machinery. Each node is real biochemistry, and the deficiency biology is genuine (methionine/choline-deficient diets reliably cause fatty liver in animals). But the honest grading stays component-level and mostly low: the deficiency-correction evidence is real, the blend-as-fat-loss-therapy claim is a hypothesis, and the convergent "lipotropic" model has never been tested as the injected combination.

No validated blend dose — only per-component volume math.

Lipo-C has no FDA-approved indication, label, or validated dose. Because it's a fixed-concentration compounded blend, dosing is by injection volume (mL), and the calculator below translates a volume into the delivered milligrams of each component using a published example concentration (methionine 15 / choline chloride 50 / L-carnitine 50 / dexpanthenol 5 mg/mL). Common practice centers on ~1 mL IM weekly, but that's a practice pattern, not evidence-based dosing. The genuinely stronger evidence is for the individual components taken orally at gram-level doses — which don't convert to these small injection volumes. Everything here is a research/education scaffold for the page calculator, not patient instructions; this is a compounded, non-approved product.

A blend that's already a stack.

Lipo-C is itself a multi-component stack, so the real question is what people add on top — and the honest answer is "things that don't have combination evidence." The most plausible "combination" is the one that does the actual work: diet and exercise, with Lipo-C as an adjunct rather than the driver. It's frequently paired with GLP-1 therapy (where the GLP-1 drives weight loss and Lipo-C is positioned for energy/adherence) and with B12/B-complex (a common clinic pattern that only helps if there's a real deficiency). Stacking it with oral L-carnitine or inositol leans on genuine ingredient evidence but risks duplication and additive GI/odor effects. The hard constraint mirrors the other compounded injectables: avoid non-essential injectable stacking in pregnancy, active cancer therapy, severe organ disease, or drug-tested athletes without review.

Mostly tolerable — with compounding and blend-unknown caveats.

At typical practice volumes Lipo-C's component nutrients are individually well-characterized and generally tolerable, so the realistic day-to-day issues are practical: injection-site reactions, the sterility/quality of a compounded product, GI upset, and a fishy body odor from carnitine/choline metabolism (trimethylamine). The deeper caveat is that the exact injectable blend has no robust human safety database of its own — tolerability is inferred from the ingredients, not demonstrated for the combination. Two specific cautions are worth flagging: the SAMe pathway (from methionine) can theoretically worsen mania in bipolar disorder, and the carnitine/choline → TMAO pathway is a slow cardiovascular consideration in susceptible people. As with any compounded injectable, the biggest real-world risks are product quality and using the shot in place of evaluation of whatever's driving fatigue or weight gain.

Practical safety framework

Contraindications & cautions

Real component evidence, no blend trial.

Lipo-C's evidence pattern is the metabolic-cofactor version of the GLOW/KLOW story: genuine human evidence exists in this space, but none of it is for the injected blend. The exact Lipo-C combination has no robust RCT. What does have evidence — and earns Grade B — is the individual components, mostly as oral supplements: L-carnitine meta-analyses for modest body-weight reduction and improved liver enzymes; inositol systematic reviews for BMI in selected (PCOS/metabolic) populations; and choline in parenteral-nutrition deficiency, where it reverses hepatic steatosis. Methionine/choline-deficient animal models give the mechanistic plausibility (Grade C), and broad reviews of fat-modifying supplements caution that most such claims have limited clinical evidence (Grade D). So Lipo-C is biologically plausible and component-supported, but its own blend-level efficacy for weight loss is unproven — and the supporting studies use different routes and gram-level doses.

Lipo-C vs MIC, its components, and the cofactor neighbors.

The clearest way to place Lipo-C is against the base MIC blend and the individual components. Lipo-C is essentially MIC (methionine + inositol + choline) plus L-carnitine and usually a B-vitamin — the same lipotropic logic with a mitochondrial fatty-acid-shuttle arm added. As with the peptide blends, the combination's evidence is weaker than the sum of its parts: each component has a clearer, route-specific identity and evidence base than the injected mixture. The throughline holds — the ingredients are real and partly evidence-backed (orally), but the injectable "Lipo-C" blend is a compounded marketing construct without its own trial. The table also contrasts it with the atlas's other non-peptide metabolic entries (L-carnitine, B-12) to keep the category map honest.

Related compounds.

Because Lipo-C is not a peptide, these are functional-neighbor compounds — lipotropic and metabolic-cofactor relatives — rather than related peptides.

The same blend, three depths.

Source register.

Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. The pattern is the metabolic-cofactor version of the GLOW/KLOW blends: the Grade-B sources are human meta-analyses and deficiency studies of individual components — oral L-carnitine for weight and liver enzymes, inositol for BMI, choline in parenteral-nutrition deficiency — never the injected blend. The methionine/choline-deficiency biology is Grade C; identity, compounding, and regulatory records are Grade D; and the broad fat-modifying-supplement review is Grade D. There is no Grade-A or direct-combination source for Lipo-C. The grade distribution makes the page's core point visible: Lipo-C's genuine evidence belongs to its components taken orally, not to the compounded injection that's actually marketed.

More Metabolic peptides & tools.